Latest Insider Transactions at Dexcom Inc (DXCM)
This section provides a real-time view of insider transactions for Dexcom Inc (DXCM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of DEXCOM INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of DEXCOM INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.61%
|
$153,000
$612.26 P/Share
|
|
Nov 23
2021
|
Sadie Stern EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
1,195
-9.2%
|
$731,340
$612.26 P/Share
|
|
Nov 22
2021
|
Barry J. Regan EVP Operations |
SELL
Open market or private sale
|
Direct |
837
-6.2%
|
$534,006
$638.65 P/Share
|
|
Nov 22
2021
|
Sadie Stern EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
856
-6.18%
|
$546,128
$638.65 P/Share
|
|
Nov 15
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
3,000
-0.49%
|
$1,944,000
$648.5 P/Share
|
|
Nov 15
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Bona fide gift
|
Direct |
250
-1.92%
|
-
|
|
Nov 12
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Bona fide gift
|
Direct |
3,000
-3.31%
|
-
|
|
Nov 09
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Grant, award, or other acquisition
|
Direct |
634
-4.69%
|
$401,956
$634.12 P/Share
|
|
Nov 03
2021
|
Richard Alexander Collins Director |
SELL
Open market or private sale
|
Indirect |
1,500
-17.23%
|
$970,500
$647.05 P/Share
|
|
Nov 01
2021
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
500
-0.34%
|
$312,500
$625.76 P/Share
|
|
Oct 29
2021
|
Nicholas Augustinos Director |
SELL
Open market or private sale
|
Direct |
2,500
-73.14%
|
$1,500,000
$600.03 P/Share
|
|
Oct 22
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.61%
|
$142,500
$570.0 P/Share
|
|
Oct 15
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
6,000
-0.71%
|
$3,300,000
$550.39 P/Share
|
|
Oct 13
2021
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
141
-1.45%
|
$76,845
$545.54 P/Share
|
|
Oct 01
2021
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
500
-0.51%
|
$271,500
$543.46 P/Share
|
|
Sep 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
6,743
-1.88%
|
$3,863,739
$573.12 P/Share
|
|
Sep 15
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
6,000
-0.75%
|
$3,240,000
$540.28 P/Share
|
|
Sep 13
2021
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
156
-1.58%
|
$84,396
$541.47 P/Share
|
|
Sep 10
2021
|
Paul R Flynn EVP Global Revenue |
SELL
Open market or private sale
|
Direct |
626
-5.42%
|
$349,308
$558.33 P/Share
|
|
Sep 10
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
681
-4.97%
|
$379,998
$558.33 P/Share
|
|
Sep 10
2021
|
Quentin S. Blackford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,519
-7.3%
|
$847,602
$558.33 P/Share
|
|
Sep 09
2021
|
Donald Abbey EVP Global Business Services I |
SELL
Open market or private sale
|
Direct |
1,263
-1.26%
|
$683,283
$541.68 P/Share
|
|
Sep 09
2021
|
Paul R Flynn EVP Global Revenue |
SELL
Open market or private sale
|
Direct |
752
-3.06%
|
$406,832
$541.56 P/Share
|
|
Sep 09
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,263
-0.89%
|
$683,283
$541.7 P/Share
|
|
Sep 09
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
987
-2.86%
|
$533,967
$541.56 P/Share
|
|
Sep 09
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,263
-1.29%
|
$683,283
$541.68 P/Share
|
|
Sep 09
2021
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
291
-1.43%
|
$157,431
$541.69 P/Share
|
|
Sep 09
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
3,017
-1.43%
|
$1,632,197
$541.32 P/Share
|
|
Sep 09
2021
|
Sumi Shrishrimal SVP Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
407
-1.61%
|
$220,187
$541.91 P/Share
|
|
Sep 09
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
407
-1.46%
|
$220,187
$541.56 P/Share
|
|
Sep 09
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Open market or private sale
|
Indirect |
5,597
-5.27%
|
$3,050,365
$545.78 P/Share
|
|
Sep 09
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
BUY
Other acquisition or disposition
|
Indirect |
2,498
+15.96%
|
-
|
|
Sep 09
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Other acquisition or disposition
|
Direct |
2,498
-15.09%
|
-
|
|
Sep 09
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,223
-1.65%
|
$1,211,535
$545.69 P/Share
|
|
Sep 09
2021
|
Quentin S. Blackford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,462
-3.29%
|
$5,156,790
$545.76 P/Share
|
|
Sep 08
2021
|
Quentin S. Blackford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,681
-10.14%
|
$4,193,826
$546.09 P/Share
|
|
Sep 07
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
587
-4.04%
|
$319,915
$545.41 P/Share
|
|
Aug 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.82%
|
$258,500
$517.24 P/Share
|
|
Aug 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,078
-0.54%
|
$555,170
$515.67 P/Share
|
|
Aug 11
2021
|
Karen M Dahut Director |
BUY
Other acquisition or disposition
|
Indirect |
387
+50.0%
|
-
|
|
Aug 11
2021
|
Karen M Dahut Director |
SELL
Other acquisition or disposition
|
Direct |
387
-18.62%
|
-
|
|
Aug 04
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Bona fide gift
|
Direct |
250
-1.55%
|
-
|
|
Aug 03
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Open market or private sale
|
Indirect |
2,757
-2.83%
|
$1,422,612
$516.06 P/Share
|
|
Jul 30
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,087
-14.63%
|
$5,753,412
$476.7 P/Share
|
|
Jul 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.74%
|
$229,000
$458.79 P/Share
|
|
Jul 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-1.06%
|
$486,629
$451.74 P/Share
|
|
Jul 16
2021
|
Sumi Shrishrimal SVP Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
400
-3.08%
|
$180,000
$450.0 P/Share
|
|
Jul 06
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Open market or private sale
|
Indirect |
2,974
-4.81%
|
$1,278,820
$430.11 P/Share
|
|
Jun 28
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.67%
|
$215,500
$431.49 P/Share
|
|
Jun 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.69%
|
$459,654
$426.37 P/Share
|